Citius Oncology, Inc. (CTOR)

Citius Oncology, Inc.'s stock (CTOR) has declined significantly over the past six months. Key events include the successful U.S. launch of LYMPHIR in December 2025, marking the transition to a revenue-generating commercial oncology business, and strategic financings to support LYMPHIR's commercialization. The company also announced positive topline results from a Phase 1 study of LYMPHIR in combination with pembrolizumab in relapsed or refractory gynecologic cancers in February 2026. In March 2026, preliminary topline Phase 1 data from a study of LYMPHIR dosing prior to commercial CAR-T therapy in high-risk diffuse large B-cell lymphoma showed a positive response rate, and the company reported commercial progress for LYMPHIR, with target accounts adding or progressing LYMPHIR through formulary review and initial accounts placing repeat orders.

The demand for LYMPHIR, Citius Oncology, Inc.'s primary product for treating cutaneous T-cell lymphoma (CTCL), is not typically subject to significant seasonality. The market for CTCL treatments is driven by the long-term needs of an afflicted patient population and a rapidly aging global population, leading to a generally stable and growing demand.

Citius Oncology, Inc. is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies, with its lead product being LYMPHIR™ (denileukin diftitox-cxdl). LYMPHIR is an FDA-approved treatment for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. Citius Oncology is a majority-owned publicly-traded subsidiary of Citius Pharmaceuticals, Inc. and is headquartered in Cranford, New Jersey.

Citius Oncology, Inc. has a commercial presence in the United States, distributing LYMPHIR nationwide through agreements with leading pharmaceutical wholesalers. The company has also initiated a global access strategy, securing access to LYMPHIR in 19 international markets through regional distribution partners via Named Patient Programs (NPPs), including an exclusive agreement with Uniphar to expand availability in Europe, the Middle East, and Turkey.

Citius Oncology's brand reputation has been positively influenced by the FDA approval of LYMPHIR for CTCL, its subsequent U.S. commercial launch, and the reporting of initial commercial revenue. The inclusion of LYMPHIR in NCCN Guidelines and the assignment of a permanent HCPCS J-code contribute to a positive perception within the medical community. Positive topline results from investigator-initiated Phase 1 studies evaluating LYMPHIR in combination therapies for other cancers have further enhanced its scientific standing and potential for future growth.

Citius Oncology, Inc. has a mixed ownership structure including institutional shareholders, insiders and retail investors. Major institutional owners include Armistice Capital LLC, Vanguard Group Inc., and Geode Capital Management, LLC. Citius Pharmaceuticals Inc. is the largest individual shareholder, owning 65.63 million shares, representing 74.34% of the company.